Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Oak

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Oak head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 539 · Grade C

Oak

Visit Oak Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 43 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Oak a bad call — it's best for readers weighing oak specifically who want to know what it does and does not publish before handing over 29 questions' worth of medical history — not readers trying to compare a price today. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
38
Supply Reliability
95
44
Transparency
90
34
Access Breadth
93
52
Clinical Oversight
92
44
Track Record
88
50
CoreAge RxBrief Score 94 · 43Oak

Price, coverage & the tracker

CoreAge RxOak
Brief Score94/100 (A)43/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

$250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

$300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning

CoverageUS only; restrictions by state, confirmed at intakeCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Oak: Prices appear before the medical questionnaire, but advertised starting figures have different conditions. The $133 semaglutide and $199 tirzepatide headlines require three-month prepayment with OAKSAVE200; confirm the final charge.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.